Tweet The diagnositic criteria for MS was updated in 2024 and these criteria were leaked in the Middle East in late 2022 and announced on the blog in 2023. This has been examined in the middle East and the 2024 criteria mean that more people are being diagnosed which is a good thing in that…
Category: Multiple Sclerosis Research
UK behind the times
Tweet Early High Efficacy treatment verses escalation from a lower efficacy agents was one of the James Lind Alliance top 10 prioritises from 2013 adopted by the MS Society Does early treatment with aggressive disease modifying drugs improve the prognosis for people with MS? The trial was adopted and at ECTRIMS 2025 we hear about…
Forms of Focus
By Stacie Prada Life is full of distractions, disruptions, deadlines, and despair. Yet we go on. Sometimes we’re strong and excited, and other times we struggle. The measure of success isn’t an imaginary idea of being perfect. Whether we lead, … Continue reading → Source: blog.mymsaa.org
New generic version of Zeposia could lower cost of MS treatment
A generic formulation of Zeposia (ozanimod), which won tentative approval for treating multiple sclerosis (MS) from the U.S. Food and Drug Administration (FDA), will be manufactured and supplied by Synthon, based […] The post New generic version of Zeposia could lower cost of MS treatment appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
ECTRIMS 2025
Tweet So we are on our way to the Late Breaking Abstracts as the show stopper for ECTRIMS….Now that we have had our fill of animal models and Sid had choked on his cornflakes we can get down to the serious stuff. So off to progression and the first one to catch my eye is…
When it comes to fight or flight, MS has made me flightless
At a recent social gathering, my military career came up, including the more than 100 parachute jumps I’ve done in my life. As usual, someone remarked that I must have […] The post When it comes to fight or flight, MS has made me flightless appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Phase 3 trial begins for at-home injectable version of Briumvi
TG Therapeutics has started enrolling participants in a Phase 3 trial to test a new version of Briumvi (ublituximab-xiiy) that can be injected at home. This change could offer greater […] The post Phase 3 trial begins for at-home injectable version of Briumvi appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
New patent covers progressive MS drug for patients in US
Immunic Therapeutics will receive a new U.S. patent covering its experimental therapy, vidofludimus calcium, and some related molecules in people with multiple sclerosis (MS). Titled “Treatment of multiple sclerosis comprising DHODH inhibitors,” […] The post New patent covers progressive MS drug for patients in US appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
ECTRIMS2025. Why could rituximab have more of an infection risk?
Tweet This week we had the suggestion that there were more infections in people treated with rituximab than oreclizumab, I suggested that there wre differences in the way that rituximab kill B cells and I also suggested that people got a third more rituximab than ocrelizumab and that it may travel round the body and…
Guest Voice: Dealing with digestive and urinary problems in MS
We all have stomach or bathroom issues from time to time. Eat the wrong thing, catch a bug, drink too much coffee, and your body will let you know. That’s […] The post Guest Voice: Dealing with digestive and urinary problems in MS appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com